Rapamycin is an immunosuppressant which antagonizes cellular proliferation by inhibiting the function of mTOR. The mTOR : FKBP12 : rapamycin complex blocks G1/S transition by inhibiting downstream targets essential for cell cycle progression. One such target is p70 S6k1 (S6K1), a serine/threonine kinase which is inactivated by the mTOR : FKBP12 : rapamycin complex, and which has been linked to translational control by virtue of its ability to phosphorylate the ribosomal protein S6. In the current work, we describe cloning and characterization of a novel S6K1 homolog, p54 S6 kinase 2 (p54 S6k2 /S6K2). Similar to S6K1, S6K2 is activated by mitogens and by constitutively active PI3K, and is inhibited by rapamycin as well as wortmannin. Dierences between activation of S6K1 and S6K2 by PDK1 were observed, suggesting potential dierences in the regulation of these homologs. Strikingly, S6K2 activity and S6 phosphorylation were both intact in S6K1 7/7 ES cell, indicating a possible role for S6K2 in in vivo S6 phosphorylation. Interestingly, we found two isoforms of S6K2 which are localized to distinct cellular compartments; the smaller form resides in the detergentsoluble fraction, whereas the larger form is found in the particulate fraction. Our ®ndings demonstrate the existence of a family of rapamycin-sensitive protein kinases potentially involved in S6 phosphorylation, translational control, and transduction of mTOR signals.
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Rapamycin is an immunosuppressant that blocks G1 to S phase cell cycle transition in many cell types. Rapamycin: FKBP12 complex binds to and inhibits the activity of mTOR (Brown et al., 1994) . Therefore studying the molecules regulated by mTOR may help us better understand cellular proliferation mechanisms. One of the ®rst proteins to be identi®ed as such an eector was p70
S6k1 (referred to as S6K1 for clarity). Studies using rapamycin as well as mutant forms of mTOR have shown that mTOR regulates S6K1 activity (Brown et al., 1995; Calvo et al., 1992; Chung et al., 1992; Kuo et al., 1992; Price et al., 1992; Terada et al., 1992) . S6K1 is a serine/threonine kinase that phosphorylates the 40S ribosomal protein S6, thereby enhancing translation of mRNAs containing a 5' polypyrimidine tract (Jeeries et al., 1994 (Jeeries et al., , 1997 Terada et al., 1994) . S6K1 activity is increased when cells are activated by various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), insulin, and serum (Chou and Blenis, 1995) . S6K1 has two isoforms, a1 (85 kDa) and a2 (70 kDa) (Grove et al., 1991) . a1 contains an N-terminal extension with a nuclear localization signal and is therefore localized predominantly in the nucleus; a2 is localized mostly in the cytoplasm (Coer and Woodgett, 1994; . Several important signaling molecules, including phosphoinositide 3-kinase (PI3K), 3-phosphoinositide-dependent protein kinase 1 (PDK1), protein kinase Cs (PKCs), Cdc42 and Rac, have been shown to regulate S6K1 activity (Alessi et al., 1998; Chou and Blenis, 1996; Chung et al., 1994; Grammer et al., 1996; Hu et al., 1995; Pullen et al., 1998; Romanelli et al., 1999; Weng et al., 1995) .
Is S6K1 the sole in vivo kinase for S6? S6K1 seems to be an important component of cell proliferation mechanism; this is evident from the observation that S6K1 7/7 embryonic stem (ES) cells exhibit a slower growth rate (Kawasome et al., 1998) . However, proliferation of the S6K1 7/7 ES cells is not completely inhibited, suggesting that there are other mechanisms that can substitute for S6K1. Moreover, S6K1 is not the only molecule whose function is inhibited by rapamycin. The activity of eukaryotic initiation factor 4E binding protein (eIF4E-BP1), cAMP-responsive element modulator (CREM), cyclin-dependent kinases, and eIF-2B kinase have all been shown to be inhibited by rapamycin (de Groot et al., 1994; Kato et al., 1994; Kleijn et al., 1998; Nourse et al., 1994; Sabers et al., 1995) . Therefore it is dicult to conclude if the cell cycle block caused by rapamycin is due to inhibition of the activity of S6K1 or other proteins. Such ®ndings suggest that elucidating other proteins in the mTOR signaling pathway, or identifying other S6K1-like molecules, is important for a better understanding of the mechanism of cellular proliferation.
In order to ®nd potential S6K1 homologs, the expressed sequence tag (EST) database was searched and a clone was found that had extensive but dispersed homology to S6K1 (Figure 1a ). Using the EST sequence information we probed a Jurkat human T cell cDNA library. Eight clones, two of which contained complete and identical open reading frames (ORF), were obtained. We have designated this clone p54
S6k2
, or S6K2 for clarity (GenBank accession number AF076931). The predicted protein molecular weight of S6K2 is 53.5 kDa, and in vitro transcription/ translation of S6K2 shows that the apparent size in SDS ± PAGE is 54 kDa (Figure 1b) .
Amino acid sequence comparison between S6K2 and S6K1 shows extensive homology ( Figure 1a ). The Nterminal acidic region found in S6K1, which is thought to inhibit kinase activity by interacting with the basic pseudosubstrate domain, is also found in S6K2. Interestingly, unlike S6K1, S6K2 contains a Cterminal proline-rich region which may be involved in SH3 domain-mediated protein-protein interaction. Protein sequence comparison also shows that human S6K2 and human S6K1 are more similar to each other than is drosophila S6K1 to either human S6K2 or S6K1, and therefore the possibility exists that the drosophila S6K1 may in fact be the drosophila S6K2. It should be noted that, unlike S6K1, S6K2 does not undergo a large mitogen-induced mobility shift (Figures 1, 3 and 4). Many important regulatory amino acids in S6K1 are also conserved in S6K2 ( Figure 1a) . Most of the C-terminal proline-directed phosphorylation sites (S403, S410, and S423), S370, and the mTOR-and PI3K-regulated phosphorylation sites (T228, S410, T388, and S403) are conserved, suggesting similar regulatory mechanisms utilized by the two proteins.
We raised antibodies against unique sequences in the C-terminal end of S6K2. One antibody (Ab), 167, yielded an immune-reactive band at approximately 54 kDa when 293 and Jurkat cell lysates were immunoblotted ( Figure 1c ). This is speci®c to the immune peptide since it could block the reactivity ( Figure 1c ). 293 cells transfected with HA-tagged S6K2 contained an additional band (HA-tagged product) at 56 kDa. In addition, in vitro transcribed/ translated S6K2 was immunoprecipitated with 167 Ab, whereas in vitro transcribed/translated S6K1 was not, further demonstrating the speci®city of 167 for S6K2 (data not shown).
In order to ascertain the agonists that increase S6K2 activity, 293 cells were treated with various mitogens and endogenous S6K2 activity assessed. Screening of dierent substrates in an in vitro kinase assay revealed that S6K2 can phosphorylate both S6 and histone H2B (data not shown), and therefore glutathione-S-transferase (GST)-tagged S6 was used as a substrate in all experiments. S6K2 was stimulated by serum and insulin, and to a lesser degree by EGF in 293 cells (Figure 1d ). Similarly, S6K1 was strongly activated by serum and insulin but only mildly activated by EGF in these cells. Figure 1e shows that both kinases were maximally activated by 30 min following serum stimulation. The activation pro®le of the HA-tagged transfected S6K2 is similar to that of endogenous S6K2 (data not shown). We generated an inactive S6K2 mutant by changing the putative catalytic lysine to arginine (S6K2 KR). Figure 1f demonstrates that the KR mutation of S6K2 abolished its kinase activity, suggesting that the kinase activity is intrinsic to S6K2 and not to an associated kinase(s).
In order to assess the signaling pathways involved in regulating S6K2 activity, the eects of pharmacological agents and mutant forms of various signaling proteins were examined. An increase in S6K2 activity by serum was inhibited by rapamycin or wortmannin ( Figure  2a ), suggesting that both PI3K and mTOR regulate S6K2 kinase activation. When 293 cells were transfected with HA-S6K2 and myc-p110*, an active form of the p110 catalytic subunit of PI3K (Weng et al., 1995) , the basal as well as the serum-stimulated S6K2 activity were increased (Figure 2b ). This is similar to S6K1 activity regulation by p110* (data not shown and Weng et al., 1995) . It has recently been demonstrated that PDK1 is a direct upstream activator of S6K1 (Alessi et al., 1998; Pullen et al., 1998) . PDK1 phosphorylates Akt/PKB at T308 in the activation loop, and it has been shown to phosphorylate the equivalent site, T229, on S6K1 (Alessi et al., 1998; Pullen et al., 1998) . We therefore assessed the role of PDK1 in S6K2 activation. Co-transfection of myc-PDK1 and HA-S6K1 showed that PDK1 enhances the basal as well as the serum-stimulated kinase activity of S6K1 (Figure 2c, right) . However, PDK1 failed to enhance the basal activity level of S6K2, but augmented serum-induced S6K2 activity (Figure 2c , left). Therefore, overexpression of PDK1 without further serum stimulation appears sucient to activate S6K1 but not S6K2. However, a kinase-inactive PDK1 K110N inhibits serum-induced activation of S6K2, indicating that PDK1 is nevertheless involved in S6K2 activation (Figure 2d ). PDK1 may phosphorylate both S6K1 and S6K2 since the phosphorylation sites are conserved in both; however, the inability of PDK1 to increase basal S6K2 activity may indicate that additional factors may be required in order to achieve basal S6K2`potentiation' in the absence of mitogenic stimuli.
We carried out immunoblots using 167 anti-S6K2 Ab in order to ascertain the cellular localization of S6K2. Soluble and particulate fractions were obtained after cells were lysed in a detergent lysis buer containing NP-40 and Brij 35, separated on SDS ± PAGE and immunoblotted with 167. We observed two distinct bands in the two fractions; the particulate fraction contained an approximate 60 kDa immunoreactive band, whereas the soluble fraction contained the 54 kDa band (Figure 3a) . Both bands reacted speci®cally with the 167 Ab, as incubation with immune peptide blocked both bands (Figure 3a) . These two forms were designated as b1 (larger) and b2 (smaller) in an eort to be consistent with the S6K1 nomenclature. The HA-tagged transfected b2 S6K2 is also found predominantly in the soluble fraction (data not shown). In order to ascertain the contents of the particulate fraction, we carried out immunoblotting using anti-lamin antibody, which revealed that the particulate fraction contains nuclear proteins (Figure 3b ). However, our soluble fraction does contain some nuclear proteins; anti-S6K1 immunoblotting shows that the a1 isoform of S6K1, which has been shown to be nuclear (Coer and Woodgett, 1994; Reinhard et al., 1994) , is found in our soluble fraction (Figure 3c ). This is an interesting observation which reveals that, under our lysis conditions, localization of the two S6K2 isoforms is distinct from that of the two S6K1 isoforms. Both b1 and b2 isoforms of S6K2 may be nuclear (Koh et al., 1999) but our data reveals they may reside in distinct nuclear compartments. Our data con®rm the speculation of existence of two S6K2 isoforms (Gout et al., 1998) , and demonstrate that their cellular localization may be distinct from that of the S6K1 isoforms.
We studied the phosphorylation status of endogenous S6 in S6K1 7/7 ES cells in order to ascertain if S6K1 is the only in vivo S6 kinase. We used the S6K1 7/7 ES cell line that was generated by homologous recombination in mouse ES cells (Kawasome et al., 1998) . Whereas immunoblots using anti-S6K1 antibody revealed absence of S6K1 in S6K1 7/7 ES cells, immunoblotting with an anti-S6K2 antiserum shows presence of S6K2 in both wildtype and S6K1
7/7
ES cells (Figure 4a ). We labeled cellular proteins in S6K1 7/7 or wildtype ES cells with 32 P and assessed the phosphorylation status of the S6 protein (Figure 4b) . We observed enhancement of in vivo phosphorylation of S6 upon serum stimulation of both wildtype and S6K1 7/7 ES cells. Phosphorylation of S6 was inhibited by rapamycin in both cell types. Our data demonstrate that S6K1 is not the only rapamycin-sensitive S6 kinase in these cells. We next assessed whether S6K2 is active under the same conditions in which S6 phosphorylation is observed in these cells. Figure 4c shows that S6K2 activity was enhanced by serum in both wildtype and S6K1 7/7 ES cells, indicating a strong correlation between S6K2 activity and endogenous S6 phosphorylation. Cloning of S6K2 was recently reported by several groups as well (Gout et al., 1998; Saitoh et al., 1998; Shima et al., 1998) . These reports have presented the cloned sequences and a brief characterization of the ectopically-expressed protein. However, there are currently many con¯icting data and unanswered questions in the ®eld regarding S6K2, and we believe our data address many of them. First, we have demonstrated that there are indeed two isoforms of S6K2, and that, moreover, the two forms are found in two distinct fractions within the cell. The fractionation conditions used reveal a signi®cant dierence between localization of S6K2 and S6K1. The two distinct forms of S6K2 may phosphorylate dierent substrates in dierent locations within the cell, thereby performing distinct functions.
Second, contrary to a previous report (Gout et al., 1998) , we clearly show that S6K2 is sensitive to rapamycin. We observe that at 20 ng/ml of rapamycin the activity of S6K2 is completely abolished, as is the case with S6K1. Third, there are also con¯icting data regarding S6K1 7/7 ES cells. Kawasome et al. (1998) showed that the S6K1 7/7 ES cells show slower growth rate and the lack of S6 phosphorylation, suggesting that S6K1 is the only S6 kinase in vivo. However, In vitro transcription/translation of S6K2 cDNA clones shows a 54 kDa product. TnT method has been previously described (Juo et al., 1998) . (c) Characterization of S6K2-speci®c Ab. 167 was raised against the C-terminal peptide IRPPSGTKKSKRGRGRPGR. Lysates from Jurkat cells, 293 cells, and 293 cells transiently transfected with HA-S6K2 (293 Tfn) were immunoblotted with 167, 167 incubated with the immunizing peptide, and the preimmune serum. Arrows indicate the bands corresponding to the endogenous and HA-tagged proteins. Transfection, lysis and immunoblots have been previously described (Romanelli et al., 1999) . (d) Stimulation of S6K2 and S6K1 activity. 293 cells were stimulated with 10% serum, 250 ng/ml EGF, or 200 nM insulin for 20 min at 37 8C. Cells were lysed, immunoprecipitated with 167 Ab or N2 anti-S6K1 Ab, and in vitro kinase assays were performed using GST-S6 as the substrate as described (Romanelli et al., 1999) Shima et al. (1998) reported that S6 is still phosphorylated in their S6K1 7/7 ES cells, proposing the existence of other S6 kinase(s). Shima et al. (1998) suggested that perhaps the dierences are due to absence or inactivity of S6K2 in the cells from Kawasome et al. (1998) . We have carried out our S6K1 7/7 experiments with the Kawasome ES cells, and ®nd that S6 is phosphorylated in these cells. Therefore our data conclude that S6K1 is not the only in vivo kinase that can phosphorylate S6. We show here that S6K2 is indeed present in these ES cells and is activated under the conditions in which S6 becomes phosphorylated.
What is the signi®cance of another S6 kinase? S6K1 had always been thought to be the only kinase of its kind, and the discovery of a S6K1 homolog underscores the importance of these kinases in cellular function, not to mention the complexities of translational control we are only now beginning to understand. Many groups have studied the role of S6K1 in cellular function by inhibiting S6K1 activity by drugs, blocking antibodies or dominant-negative versions of upstream regulators such as PI3K or PDK1. All of these studies made the assumption that S6K1 was the only S6 kinase. However, existence of another S6 kinase brings into question the speci®city of these studies. The drugs that inhibit S6K1, such as rapamycin and wortmannin, inhibit S6K2, and many of the upstream regulators of S6K1 can also regulate S6K2 activity. Therefore it is important to know that there may exist a family of S6K1-like kinases that may serve various functions in cells. Identi®cation of novel S6 kinases adds another layer of complexity to ribosomal control during translation. Given the and wildtype ES cells were immunoblotted using Ab speci®c to S6K1 or S6K2. (b) In vivo S6 phosphorylation. S6K1 7/7 or wildtype ES cells were labeled with 32 P for 2 h. Serum was added to the cells for 30 min and when indicated, rapamycin (20 ng/ml) was added to cells 20 min prior to addition of serum. In vivo labeling and isolation of S6 have been previously described . The gel was stained for assessment for equal protein loading and an autoradiogram was obtained. The level of radioactive isotope incorporation was quanti®ed using a phosphorimager. (c) Wildtype or S6K1 7/7 ES cells were stimulated with serum (25 min) and the lysates were immunoprecipitated with Ab speci®c to S6K2 or S6K1 and in vitro kinase assays were performed importance of PI3K and mTOR in cellular growth control, the identi®cation and further characterization of novel components of their signaling pathways should enhance our understanding of the processes regulated by mitogens and oncogenes.
